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Summary
To define the role of asymptomatic autoimmune
thyroiditis in the cause of breast cancer, the presence of
circulating thyroid autoantibodies was studied in two
populations, one with a high risk of breast cancer (British
women) and one with a low risk (Japanese women).
Ostensibly healthy women and patients with breast
cancer from both countries were studied. There was no
difference in the incidence of thyroid autoantibodies
between women with breast cancer and healthy women
in either race. The incidence of thyroid autoantibodies
in healthy British women, however, was two to three
times that in healthy Japanese women. The incidence of
reticulin antibodies, was considerably higher in both
groups ofJapanese women. No remarkable differences in
the incidence of antinuclear, smooth-muscle, anti-
mitochondrial, gastric parietal cell, or liver-kidney
microsomal antibodies were found between women with
breast cancer and healthy women or between the two
races. Only the incidence of antinuclear antibodies was
marginally higher in Japanese patients with advanced
cancer.
These results indicate that asymptomatic autoimmune
thyroid disease is more prevalent among British than
among Japanese women, but they fail to provide direct
evidence that autoimmune thyroid disease is associated
with breast cancer. Prospective studies of women with
autoimmune thyroiditis and studies of young women
from low-risk and high-risk populations are needed.
Introduction
The incidence of breast cancer is substantially lower in Japan
than in the West, a difference that cannot be explained entirely
by the known risk factors in breast cancer.' It has recently been
suggested that subclinical hypothyroidism may be an important
factor in the aetiology of this disease2 and that geographical
variations in the incidence of breast cancer may be related to
racial differences in thyroid status.'' Mittra et al5 have suggested,
on the basis of experimental evidence,6 that a suboptimal level
of circulating thyroid hormones may abnormally sensitise
mammary epithelial cells to prolactin stimulation, which may
lead to dysplasia and eventual neoplasia. It has recently been
established that some of the healthy population have circulating
thyroid autoantibodies indicative of asymptomatic lymphocytic
thyroiditis.8 9 Furthermore, the presence of these autoantibodies
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in some of these ostensibly healthy people is related to sub-
clinical thyroid failure, as evidenced by raised serum thyro-
trophin levels' 0-13 or abnormalities of cholesterol metabolism.14
We therefore studied the incidence of autoimmune thyroid
disease in two populations, one with a high and the other with
a low incidence of breast cancer. The incidence of circulating
thyroid autoantibodies was assessed in healthy women and those
with breast cancer from Britain and Japan.
Recent studies have suggested that the incidence of certain
non-organ-specific autoantibodies is increased in breast
cancer'5-l' and that the number of these antibodies present in
one individual is related to the risk of recurrence after mastec-
tomy.'7 Therefore we studied the incidence of antinuclear
(ANA), smooth muscle (SMA), and antimitochondrial anti-
bodies (AMA) in the two populations. We also assessed the
incidence of reticulin antibodies (RA) and liver-kidney micro-
somal (LKM) and gastric parietal cell (GPC) antibodies.
Subjects and methods
Healthy women-A total of 211 British and 96 Japanese, ostensibly
healthy, female volunteers were randomly selected for study. None of
the Japanese were in hospital, but 44 of the British women were in
hospital awaiting surgery for minor conditions unrelated to the
immune or endocrine systems. Since the incidence of the various
circulating autoantibodies in this subgroup was similar to that in the
women who were not in hospital we considered that their inclusion in
the healthy group was justified. No one with a history of thyroid
disease was accepted for study.
Patients with breast cancer-These were 277 British and 85 Japanese
women with early or advanced breast cancer who had been admitted
to the breast cancer unit at Guy's Hospital, London, or The National
Cancer Centre Hospital, Tokyo. Blood was collected from patients
with early breast cancer (defined as Ti or 2, NO or 1, and MO in the
TNM tumour classification system'8) during the 48 hours before
mastectomy. Patients with advanced breast cancer were those with
locally advanced disease or distant metastases. Most of these patients
had had, singly or in combination, oophorectomy, androgen or
oestrogen treatment, and deep x-ray treatment. None of the patients
had had hypophysectomy, adrenalectomy, or cytotoxic drugs. Blood
was collected during their admission to hospital for consideration for
endocrine ablation or deep x-ray treatment. Those with a history of
thyroid disease were not accepted.
Age-There was no statistical difference between the age distribution
in the various groups (fig 1). The age distribution of the two
subgroups of patients with breast cancer (early and advanced) was also
comparable with that of the healthy women of the same nationality.
Most women (80-900%) were aged 40 to 70 years.
Collection of blood Blood was collected from all subjects in standard
heparinised Vacutainers. Plasma was separated at 4°C and stored at
- 20°C. The Japanese samples were flown to London in a frozen
state.
Immunofluorescence and serological tests were done without prior
knowledge of the source of the plasma samples.
Immunofluorescence-Thyroid cytoplasmic (microsomal) antibodies,
ANA, SMA, AMA, RA, LKM antibodies, and GPC antibodies were
detected by indirect immunofluorescence. Cryostat sections 5-[±m
thick were cut from a composite block of tissues including human
toxic thyroid and stomach and rat stomach, liver, and kidney. Plasma
samples were tested at a dilution of 1/5. A polyvalent antihuman
8-globulin FITC conjugate was then applied and the sections were
examined with a Zeiss microscope using epi-illumination with a CSI
lamp.
Serological tests-Thyroid microsomal antibody titre was estimated
by haemagglutination and complement fixation tests. The former was
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significantly higher in the British women than in the Japanese. A
second major difference between the two races, irrespective of the
occurrence of breast cancer, was the high incidence of RA in the
Japanese (table I).
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FIG 2-Incidence of thyroid autoantibodies in healthly British
and Japanese women. IF= Immunofluorescence. CFT=
Complement fixation test. HGT= Halmagglutination test.
FIG 1-Age distribution of subejcts studied.
done by the method of Perrin and Bubell 9 starting at an initial dilution
of 1/102 (reagents supplied by Fujizoki Pharmaceutical Co). The
complement fixation antigen was a saline extract of toxic thyroid
gland. Thyroglobulin antibody was measured by a haemagglutination
test20 using tanned red cells supplied by Burroughs Welcome; a titre
of 1/20 or above was considered positive.
Statistical analysis-The data was analysed by X2 test.
Results
The incidence and the titres of circulating thyroid autoantibodies
did not differ materially between the patients with cancer and healthy
women in either. race. On comparing the incidence among healthy
women, however, important differences emerged between the two
races (fig 2). Thyroid microsomal antibodies, as detected by
immunofluorescence, were three times as common in the British as in
the Japanese women. Similarly, the incidence of these antibodies when
measured by the haemagglutination test was between three and four
times higher in the British women. The incidence of microsomal
antibodies measured by the complement fixation test and the incidence
of thyroglobulin antibodies measured by haemagglutination, although
again substantially higher in British women, were not significantly
higher than in Japanese women because of the few positive cases and
the relatively small size of the Japanese population. The overall
incidence of thyroid autoantibodies (microsomal ± thyroglobulin) was
TABLE II-Percentage incidence of multiple autoantibodies (ANA, SMA, and
AMA) in British and 3apanese women
No of No 1 >1
subjects autoantibody Autoantibody Autoantibody
British
Healthy women
Women with breast
cancer:
Early
Advanced
Total
Healthy women
Women with breast
cancer:
Early
Advanced
Total
211 71-1 26-5
69-1
648
67-1
J7apanese
71-8
65-5
53-5
57-6
149
128
277
96
29
56
85
24-8
28-1
26-4
22-9
34-5
33.9
34-1
2-3
6-0
7-0
6-5
5-2
0
12-5
8-2
There was no racial difference in the incidence, or in the titres, of
the three non-organ-specific antibodies-ANA, SMA, and AMA. The
incidence of ANA and SMA was slightly increased in patients with
cancer, although this difference was statistically significant only for
ANA in Japanese patients with advanced breast cancer (P <0 05). The
incidence ofAMA in women with cancer was similar to that in healthy
women.
Table II shows the incidence of multiple autoantibodies (combina-
tions ofANA, SMA, and AMA). Patients with breast cancer showed no
greater tendency to have multiple autoantibodies than healthy women.
TABLE I-Percentage incidence of various autoantibodies in British andJapanese women
Thyroid autoantibodies
No of Microsomal Thyroglobulin GPC
subjects Any antibodies
Immuno- Complement Haem- Haem- autoantibody
fluorescence fixation agglutination agglutinationj
ANA SMA AMA RA LKM
antibodies
19-9*
19-5
164
18 0
6-2
6-8
3-5
4-7
7-6
6-7
2-3
4-6
22-7t
22-2
17-2
19-9
British
9.9
14-7
17-9
16-2
26-0:
31-5
27-3
29-6
3-8
4-0
4-7
4-3
Japanese
2-0 6-2 5-2 12-5 1-0
0 6-8 10-3 13-7 6-8
1-7 3-5 8-9 10 7 5-3
1.1 4-7 9-4 11-7 5-8
19-4 12-3
20-8 18-8
25-0 17-9
22-7 18-4
14-5§
15-3
303
24-7
15-6
20-6
21-4
21-1
Values significantly different from those of healthy Japanese women:
*P<0-01. tP<0 005. TP<0 05. IIP<0-001.
§Values was significantly different from that for Japanese patients with advanced breast cancer (P<0 05).
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The apparent difference in the incidence of multiple autoantibodies
between Japanese women with early breast cancer and Japanese
women with advanced cancer could not be statistically evaluated
because of the small numbers studied, and may require further
examination in a larger series.
The incidence of the organ-specific antibodies (LKM and GPC
antibodies) was not significantly different in any group, although the
incidence of GPC antibody was slightly higher among Japanese
women with breast cancer.
Discussion
We observed a higher incidence of circulating thyroid auto-
antibodies in British women, a population with a high risk of
breast cancer, than in the Japanese, a population with a low
risk. This finding seems to indicate that asymptomatic auto-
immune thyroid disease is more prevalent in British women than
in Japanese women. On the other hand, the incidence of thyroid
autoantibodies in patients with established breast cancer in
either race was no higher than in their respective populations of
healthy women. Our results, therefore, fail to provide any direct
evidence that autoimmune thyroid disease is associated with
breast cancer. Additional prospective studies, in which many
women with lymphocytic thyroiditis should be followed up for
a long period, will be required to establish the precise implica-
tions of this condition in the aetiology of breast cancer. It has
been suggested that aetiological factors in breast cancer operate
only in the early reproductive years of a woman's life21 22 and
that these factors may not be apparent in case control studies
several decades later when the tumour becomes clinically
established.2' Studies in young women from high-risk and
low-risk populations, might, therefore, help to define further the
aetiological role of asymptomatic autoimmune thyroiditis in
breast cancer.
The presence of thyroid autoantibodies in over a quarter of
the adult British women studied agrees with our earlier
observations, and those of others,2' on the incidence of auto-
antibodies in middle-aged women. Similarly, an incidence of
thyroid antibodies of 9g%t) in Japanese women, reported by
Ohmi et al,24 agrees with the low incidence we observed. The
underlying factors responsible for this racial difference in
thyroid autoimmunity are unknown.
Among the other autoantibodies studies, the high incidence
of RA in the Japanese was unexpected and requires further
investigation. These antibodies included R1, R2, R, Kupffer
cell, and adherent cell types,25 the commonest being the R,
pattern, sometimes combined with Rl.
The incidence ofANA and SMA showed no racial differences.
Although patients with breast cancer had a slightly higher
incidence of ANA and SMA only the incidence of ANA in the
Japanese with advanced cancer was significantly higher than
that in healthy Japanese women. Whitehouse and Holborow
found these two antibodies in over half of their 12 patients with
breast cancer1 '-a much higher incidence than we observed.
Similarly, Wasserman et all7 reported an incidence of about
350% in patients with operable breast cancer, the incidence being
further increased to 50% in those in whom the disease recurred.
Our data on different antibodies-ANA, SMA, and AMA-
occurring singly or together in the same patient (table II), do not
support the contention of Wasserman et al'7 that multiple
autoantibodies are commoner in patients with breast cancer,
especially those who develop recurrence of disease.
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ADDENDUM-Since this paper was prepared it has been reported
that the risk of breast cancer is increased fivefold to sixfold in
women with Hashimoto's thyroiditis.'6
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